Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.1.182NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.430NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.430NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.331NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.331NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.19NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.19NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.112.3 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AY.112.3 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.37NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.37NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.110.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.110.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.180NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.180NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.155NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.155NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.92NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.92NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.145NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.145NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.120NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.120NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
A.12NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
A.12NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.417NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.417NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AM.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AM.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.258.20NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.258.20NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.36.37NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.36.37NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.319NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.319NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.46NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.46NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.139NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.139NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.508NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.508NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-21599.5US
B.1.94NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.94NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.463NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-4751.81US
B.1.1.463NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.357NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.357NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.589NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.589NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.335NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used